Portola Pharmaceuticals, Inc. News Releases http://investors.portola.com/ Portola Pharmaceuticals, Inc. News Releases en Portola Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update http://investors.portola.com/news-releases/news-release-details/portola-pharmaceuticals-reports-first-quarter-2019-financial – First Quarter Revenues of $22.2 Million;  Andexxa ® Product Revenues Grow 45% to $20.3 Million – – European Commission Approval of Ondexxya ® ; Staged Commercial Launch Planned in Second Half of 2019 – – Conference Call Today at 5:30 a.m. PT / 8:30 a.m. ET – SOUTH SAN FRANCISCO, Calif. Wed, 08 May 2019 08:01:00 -0400 Portola Pharmaceuticals, Inc. News Releases 10626 European Commission Grants Conditional Marketing Authorization for Portola Pharmaceuticals’ Ondexxya™ (andexanet alfa), the First and Only Antidote for the Reversal of Factor Xa Inhibitors http://investors.portola.com/news-releases/news-release-details/european-commission-grants-conditional-marketing-authorization – Major Advance in the Treatment of European Factor Xa Inhibitor Patients Hospitalized with Life-Threatening Bleeding – – Initial Launch in Select Countries to Begin 2H 2019 – SOUTH SAN FRANCISCO, Calif. , April 26, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. Fri, 26 Apr 2019 14:00:00 -0400 Portola Pharmaceuticals, Inc. News Releases 10616 Portola Pharmaceuticals Announces Retirement of Dr. John Curnutte, Executive Vice President and Head of Research and Development http://investors.portola.com/news-releases/news-release-details/portola-pharmaceuticals-announces-retirement-dr-john-curnutte SOUTH SAN FRANCISCO, Calif. , April 24, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. ®  (Nasdaq: PTLA) today announced that Dr. John Curnutte , M.D., Ph.D., Executive Vice President and Head of Research and Development, will retire on May 17, 2019 , after more than eight years of Wed, 24 Apr 2019 08:30:00 -0400 Portola Pharmaceuticals, Inc. News Releases 10606 Portola Pharmaceuticals to Announce First Quarter 2019 Financial Results on Wednesday, May 8, 2019 http://investors.portola.com/news-releases/news-release-details/portola-pharmaceuticals-announce-first-quarter-2019-financial SOUTH SAN FRANCISCO, Calif. , April 17, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. ® (NASDAQ: PTLA) today announced that it will host a webcast and conference call to discuss the Company’s financial results for the quarter ended March 31, 2019 , and provide a general business overview Wed, 17 Apr 2019 16:15:00 -0400 Portola Pharmaceuticals, Inc. News Releases 10586 Portola Pharmaceuticals’ Co-Founder Dr. Charles Homcy Retires from the Company’s Board of Directors http://investors.portola.com/news-releases/news-release-details/portola-pharmaceuticals-co-founder-dr-charles-homcy-retires SOUTH SAN FRANCISCO, Calif. , March 20, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) today announced that on March 15, 2019 Charles Homcy, M.D., informed the Board of his decision to retire from the Board of Directors. Dr. Homcy co-founded the Company in 2003 and served Wed, 20 Mar 2019 17:00:54 -0400 Portola Pharmaceuticals, Inc. News Releases 10561 Portola Pharmaceuticals to Webcast Presentation at Cowen and Company’s 39th Annual Health Care Conference http://investors.portola.com/news-releases/news-release-details/portola-pharmaceuticals-webcast-presentation-cowen-and-companys SOUTH SAN FRANCISCO, Calif. , March 06, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) today announced that Scott Garland , Portola’s president and chief executive officer, will present a corporate overview at Cowen and Company’s 39 th Annual Health Care Conference in Wed, 06 Mar 2019 16:10:16 -0500 Portola Pharmaceuticals, Inc. News Releases 10351 Portola Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update http://investors.portola.com/news-releases/news-release-details/portola-pharmaceuticals-reports-fourth-quarter-and-full-year-0 – Fourth Quarter Andexxa ® Revenues of $14.0 Million;  Third Consecutive Quarter of Strong Revenues – – Received Positive CHMP Opinion on Ondexxya™; European Commission Decision Anticipated in Early May – – Signed $125 Million Loan Agreement with HealthCare Royalty Partners and Athyrium Capital Fri, 01 Mar 2019 08:05:59 -0500 Portola Pharmaceuticals, Inc. News Releases 10346 Portola Pharmaceuticals Enters into $125 Million Loan Agreement with HealthCare Royalty Partners and Athyrium Capital Management http://investors.portola.com/news-releases/news-release-details/portola-pharmaceuticals-enters-125-million-loan-agreement Agreement Provides Financial Flexibility for the Ongoing Commercialization of Andexxa® and Launch Preparations in Europe SOUTH SAN FRANCISCO, Calif. , March 01, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) today announced that it has entered into a $125 million loan Fri, 01 Mar 2019 08:03:59 -0500 Portola Pharmaceuticals, Inc. News Releases 10341 European CHMP Adopts Positive Opinion on Ondexxya™ (andexanet alfa) Portola Pharmaceuticals’ Factor Xa Inhibitor Reversal Agent http://investors.portola.com/news-releases/news-release-details/european-chmp-adopts-positive-opinion-ondexxyatm-andexanet-alfa SOUTH SAN FRANCISCO, Calif. , March 01, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion on the marketing authorization Fri, 01 Mar 2019 07:38:58 -0500 Portola Pharmaceuticals, Inc. News Releases 10336 Portola Pharmaceuticals Announces Full Results from the ANNEXA-4 Study of the Factor Xa Inhibitor Reversal Agent Andexxa® in Patients with Life-Threatening Bleeding http://investors.portola.com/news-releases/news-release-details/portola-pharmaceuticals-announces-full-results-annexa-4-study – Excellent or Good Hemostasis Achieved in 82 Percent of Evaluable Patients – –Thrombotic Event Rate of 9.7 Percent Across All Patients, No Thrombotic Events Observed Among Patients Who Re-started Oral Anticoagulation Therapy – – Data Presented as a Late-Breaking Oral Presentation at the Thu, 07 Feb 2019 16:03:48 -0500 Portola Pharmaceuticals, Inc. News Releases 10331